Pharmaceutical company Johnson & Johnson has paused its COVID-19 vaccine candidate clinical trials due to an unexplained illness in a study participant.

The company made the announcement at the start of the week.

It said the participant’s illness is being reviewed and evaluated by an independent data and safety monitoring board as well as the company’s clinical and safety physicians.

The company is leading a clinical trial with 60,000-patients.

Meanwhile, in another report, Eli Lilly’s late-stage trial of its leading monoclonal antibody treatment for the coronavirus has been put on pause by U.S. health regulators over potential safety concerns, the company confirmed in a press report.

“Safety is of the utmost importance to Lilly. We are aware that, out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” a spokeswoman Molly McCully told the press.

“Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study,” she added.

Nigel Bell Readers Bureau, Contributor

Edited by Jesus Chan

Do you want to add feedback to this story?

Please add a comment in the e-mail box below, send an email to info@thereadersbureau.com,  send us a message on WhatsApp at 646-874-7976 or Call us at 201-500-7715